Clinical Trial Update: A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating venetoclax with daratumumab and dexamethasone, with or without bortezomib, in relapsed or refractory multiple myeloma; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)
• Velcade (bortezomib)
• Venclyxto (Venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING